Stocks
Atara Biotherapeutics Financial Statements (ATRA) |
||||||||||
| Atara Biotherapeuticssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 27.02.2020 | 01.03.2021 | 28.02.2022 | 08.02.2023 | 28.03.2024 | 09.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 20.3 | 63.6 | 8.57 | 34.7 | |||
| Operating Income, bln rub | -295.7 | -309.1 | -340.5 | -280.5 | -269.3 | -225.6 | ||||
| EBITDA, bln rub | ? | -295.7 | -309.1 | -340.5 | -330.8 | -264.4 | -219.1 | |||
| Net profit, bln rub | ? | -291.0 | -306.6 | -340.1 | -228.3 | -276.1 | -233.1 | |||
| OCF, bln rub | ? | -235.6 | -180.8 | -220.5 | -270.4 | -193.0 | -184.2 | |||
| CAPEX, bln rub | ? | 5.73 | 4.51 | 10.6 | 4.19 | 1.22 | 0.951 | |||
| FCF, bln rub | ? | -241.4 | -185.3 | -231.1 | -274.6 | -194.2 | -185.1 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 295.7 | 309.1 | 360.8 | 344.1 | 269.0 | 249.6 | ||||
| Cost of production, bln rub | 8.11 | 9.87 | 11.4 | 14.6 | 8.89 | 10.7 | ||||
| R&D, bln rub | 216.1 | 244.7 | 282.0 | 272.5 | 219.2 | 202.5 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.000 | 1.99 | 5.29 | 5.10 | ||||
| Assets, bln rub | 342.9 | 588.1 | 468.1 | 376.4 | 165.5 | 165.3 | ||||
| Net Assets, bln rub | ? | 290.8 | 462.3 | 279.6 | 126.6 | -99.2 | -98.3 | |||
| Debt, bln rub | 14.1 | 13.0 | 25.5 | 71.7 | 57.9 | 42.2 | ||||
| Cash, bln rub | 259.1 | 500.7 | 371.1 | 242.8 | 51.9 | 46.2 | ||||
| Net debt, bln rub | -245.0 | -487.6 | -345.6 | -171.1 | 6.00 | -4.04 | ||||
| Ordinary share price, rub | 16.5 | 19.6 | 15.8 | 3.28 | 0.513 | 1.20 | ||||
| Number of ordinary shares, mln | 51.3 | 74.0 | 93.7 | 102.0 | 105.9 | 140.6 | ||||
| Market cap, bln rub | 845 | 1 452 | 1 476 | 335 | 54 | 169 | ||||
| EV, bln rub | ? | 600 | 964 | 1 131 | 163 | 60 | 165 | |||
| Book value, bln rub | 291 | 462 | 280 | 127 | -99 | -98 | ||||
| EPS, rub | ? | -5.67 | -4.15 | -3.63 | -2.24 | -2.61 | -1.66 | |||
| FCF/share, rub | -4.70 | -2.50 | -2.47 | -2.69 | -1.83 | -1.32 | ||||
| BV/share, rub | 5.67 | 6.25 | 2.99 | 1.24 | -0.94 | -0.70 | ||||
| EBITDA margin, % | ? | -1 674% | -520.3% | -3 085% | -631.2% | |||||
| Net margin, % | ? | -1 672% | -359.1% | -3 221% | -671.7% | |||||
| FCF yield, % | ? | -28.6% | -12.8% | -15.7% | -82.1% | -357.6% | -109.7% | |||
| ROE, % | ? | -100.1% | -66.3% | -121.6% | -180.3% | 278.3% | 237.1% | |||
| ROA, % | ? | -84.8% | -52.1% | -72.7% | -60.7% | -166.8% | -141.0% | |||
| P/E | ? | -2.90 | -4.74 | -4.34 | -1.47 | -0.20 | -0.72 | |||
| P/FCF | -3.50 | -7.84 | -6.39 | -1.22 | -0.28 | -0.91 | ||||
| P/S | ? | 72.6 | 5.26 | 6.34 | 4.86 | |||||
| P/BV | ? | 2.91 | 3.14 | 5.28 | 2.64 | -0.55 | -1.72 | |||
| EV/EBITDA | ? | -2.03 | -3.12 | -3.32 | -0.49 | -0.23 | -0.75 | |||
| Debt/EBITDA | 0.83 | 1.58 | 1.01 | 0.52 | -0.02 | 0.02 | ||||
| R&D/CAPEX, % | 3 769% | 5 421% | 2 665% | 6 500% | 17 920% | 21 295% | ||||
| CAPEX/Revenue, % | 52.0% | 6.60% | 14.3% | 2.74% | ||||||
| Atara Biotherapeutics shareholders | ||||||||||
